BMJ Public Health

Gil-Prieto R, Pérez-Martín J, Díaz Aguiló A, Soudani S, Platero-Alonso L, López-Belmonte JL, de la Cuadra-Grande A, Casado MA, Alvarez Aldean J

 

 

Estimating the economically justifiable price of nirsevimab vs. Standard of Practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: A cost-utility modeling study

BMJ Public Health. 2025;3(2):e002441. doi: 10.1136/bmjph-2024-002441